PaxMedica reports first patient treated with PAX-101 for HAT

PaxMedica announced a significant milestone in its global health efforts. The Malawi Ministry of Health has informed the company that a patient suffering from the potentially fatal parasitic infection known as Human Africa Trypanosomiasis Brucei Rhodesiense, commonly referred to as African Sleeping Sickness, has recently received treatment with PAX-101, an intravenous form of Suramin, and is recovering at home. The Rhodesiense strain of Human African Trypanosomiasis is nearly 100% fatal if not treated promptly, and Suramin is considered the standard of care in Malawi, and many East African countries, in preventing death due to this parasite, when used in the early or first stage of the infection.